These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 8984483)

  • 21. [Characteristics and causes of the torpid (lingering) course of intrathoracic tuberculosis in children, the specific features of chemotherapy and outcomes].
    Iukhimenko NV; Elufimova VF; Mitinskaia LA
    Probl Tuberk Bolezn Legk; 2006; (8):29-33. PubMed ID: 17002055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of controlled clinical trials in chemotherapy of lung tuberculosis].
    Schütz I
    Prax Klin Pneumol; 1987 Mar; 41(3):69-78. PubMed ID: 3295843
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment and outcomes of disseminated pulmonary tuberculosis].
    Rzhavskov IV; Lishchinskii AB; Znosenko VA
    Probl Tuberk; 1997; (1):40-1. PubMed ID: 9162924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Symposium on the open negative syndrome. 5. Studies on the open negative syndrome occurring after chemotherapy with secondary antituberculous drugs].
    Kimura Y
    Kekkaku; 1966 Aug; 41(8):383-6. PubMed ID: 5975306
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of drug resistant tuberculosis.
    Supcharoen S
    Bull Int Union Tuberc; 1974 Aug; 49 suppl 1():286-7. PubMed ID: 4468025
    [No Abstract]   [Full Text] [Related]  

  • 26. Liver function tests in patients of pulmonary tuberculosis using four different drug regimens.
    Akbri MZ; Fatima N; ul Haque E; Shiekh AS; Bhatti MS
    J Ayub Med Coll Abbottabad; 2001; 13(2):5-10. PubMed ID: 11732224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of essential oil of peppermint (Mentha piperita) in the complex treatment of patients with infiltrative pulmonary tuberculosis].
    Shkurupiĭ VA; Odintsova OA; Kazarinova NV; Tkrachenko KG
    Probl Tuberk Bolezn Legk; 2006; (9):43-5. PubMed ID: 17128800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of pulmonary tuberculosis in patients with drug dependence].
    Zadremaĭlova TA; Aksenova KI
    Probl Tuberk Bolezn Legk; 2003; (7):31-3. PubMed ID: 12939874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):10-5. PubMed ID: 9562106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of chemotherapy for tuberculosis in patients who isolate drug-resistant strains of M. tuberculosis with different genotypes].
    Vasil'eva IA; Andreevskaia SN; Smirnova TG; Chernousova LI; Chukanov VI
    Probl Tuberk Bolezn Legk; 2004; (8):25-8. PubMed ID: 15478554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The specific features of a pathogen in acutely progressive pulmonary tuberculosis].
    Balasaniants GS; Greĭmer MS
    Probl Tuberk Bolezn Legk; 2003; (9):29-31. PubMed ID: 14598524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Changes and patterns of drug resistance of mycobacterium tuberculosis in patients with pulmonary tuberculosis (by data of the microbiological laboratory of research production association "Phthysiology")].
    Gorokhova TV
    Probl Tuberk; 1997; (2):33-5. PubMed ID: 9235582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Failures of standardized treatments in pulmonary tuberculosis. Possibilities of prevention and therapeutic recovery].
    Sava N; Stanca-Circioiu M; Gartner A; Anastasatu C
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(3):165-72. PubMed ID: 6273988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A paradoxical reaction during antituberculosis therapy for congenital tuberculosis.
    Park JA; Park SS; Park SE
    Int J Infect Dis; 2009 Sep; 13(5):e279-81. PubMed ID: 19124260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retreatment of pulmonary tuberculosis.
    Agarwal K; Roy DC; Matah SC; Sunder S
    J Assoc Physicians India; 1985 Dec; 33(12):814-6. PubMed ID: 3837007
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antitubercular chemotherapy--its current status and outlook].
    Moisescu V
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1988; 37(1):15-26. PubMed ID: 2847296
    [No Abstract]   [Full Text] [Related]  

  • 38. [Correction of bronchial obstructive syndrome and antituberculous drugs-induced eosinophilia in patients with pulmonary tuberculosis by using plasmapheresis].
    Shmelev EI; Stepanian IE
    Probl Tuberk; 1996; (6):57-60. PubMed ID: 9019774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tuberculosis associated with the human immunodeficiency virus].
    Gérard M
    Rev Med Brux; 2000 Apr; 21(2):75-83. PubMed ID: 10829599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effectiveness of the standard mode of chemotherapy for newly-diagnosed patients with destructive pulmonary tuberculosis with bacterial isolation].
    Mishin VIu; Chukanov VI; Vylegzhanin SV
    Probl Tuberk; 2001; (7):13-8. PubMed ID: 11763553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.